Briacell Therapeutics Corp Stock Price, News & Analysis

BriaCell Therapeutics (NASDAQ: BCTX) has published research validating the mechanism of action of its Bria-OTS+™ platform, a personalized, off-the-shelf cellular immunotherapy for cancer treatment. The study, conducted in collaboration with the National Cancer Institute (NCI), appeared in the peer-reviewed journal JCI Insight.

The research demonstrates that semi-allogeneic dendritic-cell vaccines can enhance anti-tumor responses through partial HLA matching and planned mismatching. This mechanism enables effective tumor-antigen presentation while driving robust CD4⁺ helper responses, supporting the clinical results observed in BriaCell's Phase 1/2a study in metastatic breast cancer.

BriaCell Therapeutics (NASDAQ: BCTX) has secured a $2.05 million non-dilutive grant from the National Cancer Institute (NCI) to advance Bria-PROS+™, its next-generation personalized off-the-shelf immunotherapy for prostate cancer. The funding will support the manufacturing and upcoming Phase 1/2a clinical trial for patients with metastatic prostate cancer.

The study will be led by Dr. William Oh from Yale Cancer Center as Principal Investigator. The Bria-OTS+ platform aims to address the challenges of traditional personalized cancer treatments by offering a more streamlined approach to immunotherapy for patients with advanced prostate cancer.

BriaCell Therapeutics (NASDAQ: BCTX), a clinical-stage biotechnology company, has announced a 1-for-10 share consolidation (reverse stock split) to maintain Nasdaq listing compliance. The consolidation is set to take effect on August 25, 2025.

Under the consolidation terms, shareholders will receive one new share for every ten existing shares. Fractional shares will be handled by rounding up fractions of ½ or greater to one whole share, while smaller fractions will be cancelled. The company's convertible securities will be proportionally adjusted.

Post-consolidation, BriaCell will continue trading under the symbols BCT on TSX and BCTX on Nasdaq. Registered shareholders will receive transmittal letters from Computershare Investor Services with exchange instructions.

BriaCell Therapeutics (NASDAQ: BCTX) has been selected to join Memorial Sloan Kettering Cancer Center's (MSK) Therapeutics Accelerator 2025 Cohort program to advance the development of its Bria-OTS+™ immunotherapy platform. The collaboration aims to accelerate the clinical development of BriaCell's next-generation personalized off-the-shelf immunotherapy for multiple cancer indications, including metastatic breast cancer and prostate cancer.

Through this program, BriaCell will gain access to MSK's extensive expertise and institutional resources, including GMP manufacturing services, IND Application support, and regulatory strategy assistance. MSK, with over 135 years of leadership in cancer care, will provide crucial support to expedite Bria-OTS+ development.

BriaCell Therapeutics (NASDAQ: BCTX), a clinical-stage biotechnology company, has announced a 1-for-10 share consolidation to maintain Nasdaq listing compliance. The consolidation is expected to take effect on August 25, 2025, with post-consolidation trading beginning around August 26, 2025, subject to TSX and Nasdaq approval.

Under the consolidation terms, shareholders will receive one new share for every ten existing shares. Fractional shares will be handled by rounding up fractions of ½ or greater to one whole share, while smaller fractions will be cancelled. The company's convertible securities will be proportionally adjusted, and trading symbols will remain unchanged on both exchanges.

BriaCell Therapeutics (NASDAQ: BCTX) has announced the addition of UCLA Health Jonsson Comprehensive Cancer Center as a key site for its pivotal Phase 3 clinical study (Bria-ABC). The study evaluates Bria-IMT™ combined with a checkpoint inhibitor versus physician's choice in advanced metastatic breast cancer patients.

The trial's interim analysis will be conducted after 144 patient events, with overall survival as the primary endpoint. Building on positive Phase 2 survival data presented at ASCO 2025, the study has received FDA Fast Track designation. BriaCell expects to share top-line data in 2026.

BriaCell Therapeutics (NASDAQ: BCTX) has secured New Zealand Patent No. 785587 for its whole-cell cancer immunotherapy technology. The patent, valid through February 27, 2037, covers methods for selecting cancer immunotherapy based on HLA allele profile matching.

This development strengthens BriaCell's precision medicine approach, focusing on personalizing immunotherapy for enhanced patient outcomes. The patent is part of the company's broader strategy to build a robust international patent portfolio for global development and commercialization across multiple cancer indications.

BriaCell Therapeutics (NASDAQ: BCTX) and its subsidiary BriaPro have announced the filing of a patent application for their novel TILsRx immunotherapy platform. The platform is designed to develop multivalent agents that can simultaneously target multiple cancer-associated and immune pathway targets.

The technology focuses on activating tumor-infiltrating lymphocytes (TILs) and includes key components such as soluble CD80, anti-CD3, IL-21, and anti-STEAP1. An early candidate target is B7-H3, which is overexpressed in multiple cancers including prostate, lung, breast, pancreatic, and ovarian cancer.

The platform aims to provide improved clinical responses while minimizing off-target toxicity, with the flexibility to incorporate new immunotherapy targets as they are identified.

BriaCell Therapeutics (NASDAQ: BCTX) has announced two clinical data poster presentations at the upcoming ESMO Congress 2025 in Berlin, Germany. The presentations will focus on the company's Phase III pivotal trial of Bria-IMT combined with CPI for advanced metastatic breast cancer treatment.

The two posters (#8212 and #3928) will present data on the BRIA-ABC trial, examining both the pivotal trial results and the feasibility and biomarker validation aspects of this international randomized Phase 3 study. The abstracts will be published on the ESMO website on October 13th, 2025, with the congress taking place from October 17-21, 2025.